https://orcid.org/0000-0002-1180-9978
References
- U.S. overdose deaths in 2021 increased half as much as in 2020 - but are still up 15% [Internet]. Centers for Disease Control and Prevention; 2022 [cited 2022 Dec 29]. Available from: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm
- Koehl JL, Zimmerman DE, Bridgeman PJ. Medications for management of opioid use disorder. Am J Health-Syst Pharm. 2019;76(15):1097–103. doi:10.1093/ajhp/zxz105.
- Virk MS, Arttamangkul S, Birdsong WT, Williams JT. Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009;29(22):7341–7348. doi:10.1523/JNEUROSCI.3723-08.2009.
- Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2003;
- Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC. Concurrent validation of the clinical opiate withdrawal scale (cows) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009;105(1–2):154–9. doi:10.1016/j.drugalcdep.2009.07.001.
- Vogel M, Hämmig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: The “bernese method.” Subst Abuse Rehabil. 2016;7:99–105. doi:10.2147/SAR.S109919.
- Tay Wee Teck J, Baldacchino A, Gibson L, Lafferty C. Using microdosing to induct patients into a long-acting injectable buprenorphine depot medication in low threshold community settings: a case study. Front Pharmacol. 2021;12. doi:10.3389/fphar.2021.631784.
- Raheemullah A, Lembke A. Buprenorphine induction without opioid withdrawal. Am J Therap. 2019. Epub ahead of print. doi:10.1097/MJT.0000000000001108.
- Ghosh SM, Klaire S, Tanguay R, Manek M, Azar P. A review of novel methods to support the transition from methadone and other full agonist opioids to buprenorphine/naloxone sublingual in both community and Acute Care Settings. Can J Addict. 2019;10(4):41–50. doi:10.1097/CXA.0000000000000072.
- Baumgartner K, Salmo E, Liss D, Devgun J, Mullins M, Galati B, et al. Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study. Clin Toxicol. 2022;60(6):688–93. doi:10.1080/15563650.2022.2028802.
- Weimer MB, Guerra M, Morrow G, Adams K. Hospital-based Buprenorphine micro-dose Initiation. J Addict Med. 2021;15(3):255–257. doi:10.1097/ADM.0000000000000745.
- Buprenorphine transdermal system (Butrans). [Internet]. US Food and Drug Administration; 2014 [cited 2022 Dec 29]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021306s015s019lbl.pdf.
- Button D, Hartley J, Robbins J, Levander XA, Smith NJ, Englander H. Low-dose Buprenorphine initiation in hospitalized adults with opioid use disorder: a retrospective cohort analysis. J Addict Med. 2022;16(2):e105–e111. doi:10.1097/ADM.0000000000000864.
- Harris SC, Morganroth J, Ripa SR, Thorn MD, Colucci S. Effects of buprenorphine on qt intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials. Postgrad Med. 2017;129(1):69–80. doi:10.1080/00325481.2017.1270156.